The WACC of Nabriva Therapeutics PLC (NBRV) is 7.4%.
| Range | Selected | |
| Cost of equity | 7.00% - 10.20% | 8.60% |
| Tax rate | 0.80% - 1.40% | 1.10% |
| Cost of debt | 5.70% - 7.00% | 6.35% |
| WACC | 6.3% - 8.4% | 7.4% |
| Category | Low | High |
| Long-term bond rate | 4.2% | 4.7% |
| Equity market risk premium | 5.0% | 6.0% |
| Adjusted beta | 0.57 | 0.83 |
| Additional risk adjustments | 0.0% | 0.5% |
| Cost of equity | 7.00% | 10.20% |
| Tax rate | 0.80% | 1.40% |
| Debt/Equity ratio | 1.15 | 1.15 |
| Cost of debt | 5.70% | 7.00% |
| After-tax WACC | 6.3% | 8.4% |
| Selected WACC | 7.4% | |
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for NBRV:
cost_of_equity (8.60%) = risk_free_rate (4.45%) + equity_risk_premium (5.50%) * adjusted_beta (0.57) + risk_adjustments (0.25%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.